Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Raised to “Hold” at Zacks Research

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) was upgraded by Zacks Research from a “strong sell” rating to a “hold” rating in a report released on Monday,Zacks.com reports.

A number of other research firms also recently commented on KNSA. Wells Fargo & Company lifted their target price on Kiniksa Pharmaceuticals International from $53.00 to $57.00 and gave the stock an “overweight” rating in a report on Wednesday, April 29th. Weiss Ratings raised Kiniksa Pharmaceuticals International from a “hold (c)” rating to a “hold (c+)” rating in a report on Wednesday, May 6th. Citigroup boosted their price target on Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the company a “buy” rating in a report on Wednesday, April 29th. Canaccord Genuity Group boosted their price target on Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the company a “buy” rating in a report on Wednesday, April 29th. Finally, Wedbush boosted their price target on Kiniksa Pharmaceuticals International from $58.00 to $59.00 and gave the company an “outperform” rating in a report on Wednesday, April 29th. Seven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $60.86.

Kiniksa Pharmaceuticals International Trading Down 0.6%

Shares of Kiniksa Pharmaceuticals International stock opened at $53.34 on Monday. The firm has a market cap of $4.10 billion, a P/E ratio of 59.27 and a beta of 0.17. Kiniksa Pharmaceuticals International has a 12 month low of $25.70 and a 12 month high of $59.87. The stock’s fifty day moving average price is $48.98 and its 200-day moving average price is $44.61.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings data on Tuesday, April 28th. The company reported $0.27 earnings per share for the quarter, beating analysts’ consensus estimates of $0.18 by $0.09. Kiniksa Pharmaceuticals International had a return on equity of 13.26% and a net margin of 9.69%.The company had revenue of $214.27 million for the quarter, compared to the consensus estimate of $206.11 million. During the same quarter last year, the company earned $0.11 earnings per share. The firm’s revenue for the quarter was up 55.5% compared to the same quarter last year. Analysts forecast that Kiniksa Pharmaceuticals International will post 1.24 earnings per share for the current year.

Insider Buying and Selling

In related news, COO Ross Moat sold 2,367 shares of Kiniksa Pharmaceuticals International stock in a transaction on Monday, April 6th. The shares were sold at an average price of $48.58, for a total value of $114,988.86. Following the sale, the chief operating officer owned 12,029 shares of the company’s stock, valued at approximately $584,368.82. This trade represents a 16.44% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Sanj K. Patel sold 483,654 shares of the business’s stock in a transaction on Tuesday, April 28th. The stock was sold at an average price of $51.86, for a total transaction of $25,082,296.44. Following the completion of the sale, the chief executive officer directly owned 431,904 shares of the company’s stock, valued at approximately $22,398,541.44. The trade was a 52.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 653,301 shares of company stock valued at $34,046,073 in the last three months. 51.98% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of KNSA. Mark Sheptoff Financial Planning LLC increased its stake in Kiniksa Pharmaceuticals International by 1.6% during the 4th quarter. Mark Sheptoff Financial Planning LLC now owns 16,350 shares of the company’s stock worth $674,000 after buying an additional 250 shares in the last quarter. Mariner LLC increased its position in shares of Kiniksa Pharmaceuticals International by 2.0% during the fourth quarter. Mariner LLC now owns 13,519 shares of the company’s stock worth $558,000 after purchasing an additional 266 shares in the last quarter. First Trust Advisors LP raised its stake in Kiniksa Pharmaceuticals International by 3.1% in the 1st quarter. First Trust Advisors LP now owns 9,876 shares of the company’s stock valued at $476,000 after purchasing an additional 293 shares during the last quarter. Virtus Investment Advisers LLC raised its stake in Kiniksa Pharmaceuticals International by 2.5% in the 4th quarter. Virtus Investment Advisers LLC now owns 16,432 shares of the company’s stock valued at $678,000 after purchasing an additional 406 shares during the last quarter. Finally, Mercer Global Advisors Inc. ADV raised its stake in Kiniksa Pharmaceuticals International by 7.1% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 7,684 shares of the company’s stock valued at $317,000 after purchasing an additional 508 shares during the last quarter. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.